Trimbow
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Trimbow ([beclomethasone + formoterol + glycopyrrolate]; Chiesi Farmaceutici) is a fixed triple-combination product consisting of glycopyrrolate (a LAMA), formoterol (a LABA), and beclometasone (an ICS), used to relieve the symptoms of moderate to severe chronic obstructive pulmonary disease (COPD). Trimbow’s market potential will ultimately be limited by its restricted geographic scope, as it has only been developed for the European market. Although the drug was the first inhaled corticosteroid/long-acting beta 2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) to launch in the EU, GlaxoSmithKline’s Trelegy Ellipta ([fluticasone furoate + umeclidinium + vilanterol]) was approved just four months later, significantly reducing the impact of Trimbow’s first-to-market status. Further competition will likely come from AstraZeneca’s PT010 ([budesonide + glycopyrrolate + formoterol]), which is expected to launch in the European markets from Q1 2021. Datamonitor Healthcare believes Chiesi Farmaceutici will not seek regulatory approval in the US or Japan, meaning Trimbow will remain limited to the European market.
TABLE OF CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Trimbow : Chronic obstructive pulmonary disease (COPD)
LIST OF FIGURES
10 Figure 55: Tudorza Pressair sales for COPD across the US, Japan, and major EU markets, by country, 2017–26
12 Figure 67: Datamonitor Healthcare’s drug assessment summary of Ultibro/Utibron for COPD
14 Figure 68: Datamonitor Healthcare’s drug assessment summary of Ultibro/Utibron for COPD
LIST OF TABLES
5 Table 1: Trimbow drug profile
7 Table 2: Trimbow Phase III data in COPD
9 Table 3: Trimbow Phase III trial in COPD
15 Table 4: Trimbow sales for COPD across the five major EU markets, by country ($m), 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Utibron Neohaler 
Sign up to the